Aragen Life Sciences IPO

Initial public offer of up to [] equity shares of face value of Rs.10/- each (equity shares) of Aragen Life Sciences Limited (company or issuer) for cash at a price of Rs.[] per equity share (including a share premium of Rs.[] per equity share) (offer price) aggregating up to Rs.[] crores comprising a fresh issue of up to [] equity shares of face value of Rs.10/- each aggregating up to Rs.800.00 crores by the company (fresh issue) and an offer for sale of up to 27,329,192 equity shares of face value of Rs.10/- each aggregating up to Rs.[] crores by the selling shareholders, comprising an offer for sale of up to 1,863,354 equity shares of face value of Rs.10/- each aggregating up to Rs.[] crores by Reddy Investment Trust and up to 621,118 shares of face value of Rs.10/- each aggregating up to Rs.[] crores by Davinder Singh Brar, (Reddy Investment Trust and Davinder Singh Brar together referred to as promoter selling shareholders), up to 18,460,361 equity shares of face value of Rs.10/- each aggregating up to Rs.[] crores by WSCPVIII (Singapore) Pte. Ltd., up to 3,323,006 equity shares of face value of Rs.10/- each aggregating up to Rs.[] crores by WSCPVIII EMP (Singapore) Pte. Ltd., up to 2,565,193 equity shares of face value of Rs.10/- each aggregating up to Rs.[] crores by Goldman Sachs Capital Holdings III Pte. Ltd., and up to 496,160 equity shares of face value of Rs.10/- each aggregating up to Rs.[] crores by WSCPVIII Pparallel Intermediary (Singapore) Pte. Ltd., (WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd., along with WSCPVIII (Singapore) Pte. Ltd, WSCPVIII EMP(Singapore) Pte. Ltd. and Goldman Sachs Capital Holdings III Pte. Ltd. investor selling shareholders), (the promoter selling shareholder and the investor selling shareholders, shall be referred to as the selling shareholders and such equity shares offered by the selling shareholders (offered shares) and such offer, offer for sale, and together with the fresh issue, the offer). The company, in consultation with the brlms, may consider a pre-ipo placement of equity shares, as may be permitted under applicable law aggregating up to Rs. 160 crores, prior to filing of the roc. The pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the brlms. if the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) Rules, 1957, as amended. The pre-ipo placement, if undertaken, shall not exceed 20% of the size of the fresh issue. prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the offer or the offer may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if undertaken). The offer includes a reservation of up to [] equity shares of face value of Rs. 10/-, aggregating up to Rs.[] crores (constituting up to []% of the post-offer paid-up equity share capital), for subscription by eligible employees (employee reservation portion). The company, in consultation with the brlms may offer a discount of Rs.[] per equity share of face value of Rs. 10/- each, to eligible employees bidding in the employee reservation portion (employee discount), subject to necessary approvals as may be required. the offer less the employee reservation portion is hereinafter referred to as the net offer. The offer and the net offer shall constitute [] % and [] % of the post-offer paid-up equity share capital of the company, respectively. The face value of equity shares is Rs.10/- each. The offer price is [*] times the face value of the equity shares. The price band and the minimum bid lot and the employee discount will be decided by the company.